Skip to main content
Signal8
Launch Terminal

Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Summit Therapeutics Inc. logo

Summit Therapeutics Inc.

NASDAQ:SMMTHealthcare
-1.05%$16.03
AH$15.98-0.32%vs close
Mkt Cap$12.79B
Float138.49M
O/S797.75M
Vol
$ Vol
RVOL
Inst Own17.2%
Earnings
Dilution
Summit Therapeutics Inc. logoNASDAQ:SMMT$16.03-1.05%
Upcoming Catalysts
  • ivonescimabPDUFA
    EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer after prior third-generation EGFR TKI
    Cash runway at this date: 14mo
    Nov 14, 2026in 12 daysPR
  • ivonescimabREADOUT
    Cash runway at this date: 15mo
    Oct 25, 20268d agoPR
Phase Distribution
13 lead-sponsored trials·5 active·5 completed
Phase 12
Phase 24
Phase 2/31
Phase 36
(28 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Recent Deals
  • Lunit Inc.COLLAB
    Oct 24, 2026
    ivonescimabLunit SCOPE IO
  • Lunit Inc.COLLAB
    Oct 23, 2026
    ivonescimabLunit SCOPE IO
  • ECOG-ACRIN Cancer Research GroupCOLLAB
    Oct 21, 2026
    ivonescimab (SMT112)EA2251 (NCT07765433)
  • ECOG-ACRIN Cancer Research GroupCOLLAB
    Jan 1, 1970
    ivonescimabEA2251
Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

    Ridinilazole, Vancomycin

    Clostridioides Difficile Infection

    Enrollment
    759
    Start
    Jan 2019
    Primary Completion
    Nov 2021
    Completion
    Nov 2021
    NCT03595553
  • Phase 3
    Terminated

    Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

    Ridinilazole, Vancomycin

    Clostridioides Difficile Infection

    Enrollment
    2
    Start
    May 2021
    Primary Completion
    Sep 2021
    Completion
    Sep 2022
    NCT04802837
  • Phase 3
    Active, not recruiting

    Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

    Ivonescimab Injection, Pembrolizumab Injection

    Non-Small Cell Lung Cancer

    Enrollment
    1,600
    Start
    Oct 2023
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2029est.
    NCT05899608
  • Phase 3
    Active, not recruiting

    Phase III Study of AK112 for NSCLC Patients

    AK112 Injection, Placebo Injection

    Non-Squamous Non-small Cell Lung Cancer

    Enrollment
    420
    Start
    May 2023
    Primary Completion
    Apr 2025
    Completion
    Dec 2026est.
    NCT06396065
  • Phase 3
    Recruiting

    Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Ivonescimab Injection, Pembrolizumab Injection

    Non-Small Cell Lung Cancer

    Enrollment
    780
    Start
    Feb 2025
    Primary Completion
    Apr 2028est.
    Completion
    Jun 2029est.
    NCT06767514
  • Phase 3
    Recruiting

    Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    Drug: Ivonescimab Injection, Drug: Bevacizumab Injection

    Metastatic Colorectal Cancer (CRC)

    Enrollment
    600
    Start
    Nov 2025
    Primary Completion
    May 2028est.
    Completion
    Nov 2029est.
    NCT07228832
  • Phase 2/3
    Recruiting

    A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

    Ivonescimab Dose 1, enfortumab vedotin (EV)

    Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)

    Enrollment
    800
    Start
    Sep 2026est.
    Primary Completion
    Oct 2030est.
    Completion
    Dec 2030est.
    NCT07815665
  • Phase 2
    Completed

    A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

    SMT19969, Vancomycin

    Clostridium Difficile Infection

    Enrollment
    100
    Start
    Apr 2014
    Primary Completion
    Oct 2015
    Completion
    Oct 2015
    NCT02092935
  • Phase 2
    Completed

    A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

    Ridinilazole, Fidaxomicin

    Clostridium Difficile Infection

    Enrollment
    27
    Start
    Dec 2014
    Primary Completion
    Aug 2016
    Completion
    Aug 2016
    NCT02784002
  • Phase 2
    Terminated

    Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD)

    Ezutromid

    Duchenne Muscular Dystrophy

    Enrollment
    43
    Start
    Jun 2016
    Primary Completion
    Apr 2018
    Completion
    Sep 2018
    NCT02858362
  • Phase 2
    Not yet recruiting

    A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer

    Ivonescimab (dose level 1) combined with Cadonilimab, Ivonescimab (dose level 2) combined with Cadonilimab

    Renal Cell Carcinoma, Clear Cell

    Enrollment
    100
    Start
    Oct 2026est.
    Primary Completion
    Apr 2029est.
    Completion
    Dec 2029est.
    NCT07877194
  • Phase 1
    Completed

    A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)

    SMT C1100

    Duchenne Muscular Dystrophy

    Enrollment
    12
    Start
    Nov 2013
    Primary Completion
    May 2014
    Completion
    Jul 2014
    NCT02056808
  • Phase 1
    Completed

    Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet

    SMT C1100, SMT C1100

    Muscular Dystrophy, Duchenne

    Enrollment
    12
    Start
    Feb 2015
    Primary Completion
    Aug 2015
    Completion
    Aug 2015
    NCT02383511
Search ClinicalTrials.gov for “Summit Therapeutics”